50 related articles for article (PubMed ID: 9309140)
21. MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta.
Woodings JA; Sharp SJ; Machesky LM
Biochem J; 2003 Apr; 371(Pt 2):463-71. PubMed ID: 12570871
[TBL] [Abstract][Full Text] [Related]
22. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
Nur-E-Kamal MS; Kamal JM; Qureshi MM; Maruta H
Oncogene; 1999 Dec; 18(54):7787-93. PubMed ID: 10618719
[TBL] [Abstract][Full Text] [Related]
23. Properties of an ezrin mutant defective in F-actin binding.
Saleh HS; Merkel U; Geissler KJ; Sperka T; Sechi A; Breithaupt C; Morrison H
J Mol Biol; 2009 Jan; 385(4):1015-31. PubMed ID: 19084535
[TBL] [Abstract][Full Text] [Related]
24. The coiled-coil domain is required for HS1 to bind to F-actin and activate Arp2/3 complex.
Hao JJ; Zhu J; Zhou K; Smith N; Zhan X
J Biol Chem; 2005 Nov; 280(45):37988-94. PubMed ID: 16157603
[TBL] [Abstract][Full Text] [Related]
25. Two tandem verprolin homology domains are necessary for a strong activation of Arp2/3 complex-induced actin polymerization and induction of microspike formation by N-WASP.
Yamaguchi H; Miki H; Suetsugu S; Ma L; Kirschner MW; Takenawa T
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12631-6. PubMed ID: 11058146
[TBL] [Abstract][Full Text] [Related]
26. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
He H; Hirokawa Y; Manser E; Lim L; Levitzki A; Maruta H
Cancer J; 2001; 7(3):191-202. PubMed ID: 11419027
[TBL] [Abstract][Full Text] [Related]
27. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants.
Pineda-Lucena A; Ho CS; Mao DY; Sheng Y; Laister RC; Muhandiram R; Lu Y; Seet BT; Katz S; Szyperski T; Penn LZ; Arrowsmith CH
J Mol Biol; 2005 Aug; 351(1):182-94. PubMed ID: 15992821
[TBL] [Abstract][Full Text] [Related]
28. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2.
Xu XX; Yi T; Tang B; Lambeth JD
Oncogene; 1998 Mar; 16(12):1561-9. PubMed ID: 9569023
[TBL] [Abstract][Full Text] [Related]
29. The C-terminus SH3-binding domain of Kv1.3 is required for the actin-mediated immobilization of the channel via cortactin.
Hajdu P; Martin GV; Chimote AA; Szilagyi O; Takimoto K; Conforti L
Mol Biol Cell; 2015 May; 26(9):1640-51. PubMed ID: 25739456
[TBL] [Abstract][Full Text] [Related]
30. Role of cortactin homolog HS1 in transendothelial migration of natural killer cells.
Mukherjee S; Kim J; Mooren OL; Shahan ST; Cohan M; Cooper JA
PLoS One; 2015; 10(2):e0118153. PubMed ID: 25723543
[TBL] [Abstract][Full Text] [Related]
31. Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin.
Campbell DH; Sutherland RL; Daly RJ
Cancer Res; 1999 Oct; 59(20):5376-85. PubMed ID: 10537323
[TBL] [Abstract][Full Text] [Related]
32. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites.
Schuuring E; Verhoeven E; Litvinov S; Michalides RJ
Mol Cell Biol; 1993 May; 13(5):2891-98. PubMed ID: 8474448
[TBL] [Abstract][Full Text] [Related]
33. Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells.
Butler B; Kastendieck DH; Cooper JA
Nat Immunol; 2008 Aug; 9(8):887-97. PubMed ID: 18587398
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells.
Koya Y; Liu W; Yamakita Y; Senga T; Shibata K; Yamashita M; Nawa A; Kikkawa F; Kajiyama H
Oncotarget; 2018 Aug; 9(66):32609-32623. PubMed ID: 30220969
[TBL] [Abstract][Full Text] [Related]
35. 3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells.
Sampietro M; Zamai M; Díaz Torres A; Labrador Cantarero V; Barbaglio F; Scarfò L; Scielzo C; Caiolfa VR
Front Cell Dev Biol; 2021; 9():655773. PubMed ID: 34277604
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic lineage cell-specific protein 1 immunoreactivity indicates an increased risk of poor overall survival in patients with ovarian carcinoma.
Liu W; Kajiyama H; Shibata K; Koya Y; Senga T; Kikkawa F
Oncol Lett; 2018 Jun; 15(6):9406-9412. PubMed ID: 29805664
[TBL] [Abstract][Full Text] [Related]
37. [HS1 and EMS1].
He H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1448-53. PubMed ID: 9309140
[TBL] [Abstract][Full Text] [Related]
38. Cortactin regulates cell migration through activation of N-WASP.
Kowalski JR; Egile C; Gil S; Snapper SB; Li R; Thomas SM
J Cell Sci; 2005 Jan; 118(Pt 1):79-87. PubMed ID: 15585574
[TBL] [Abstract][Full Text] [Related]
39. Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation.
He H; Watanabe T; Zhan X; Huang C; Schuuring E; Fukami K; Takenawa T; Kumar CC; Simpson RJ; Maruta H
Mol Cell Biol; 1998 Jul; 18(7):3829-37. PubMed ID: 9632767
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
